GOOD AFTERNOON, EVERYONE.
I'M CALLING THE MEETING TO
ORDER.
I'M DR. GERRY PARKER FOR BIO
SECURITY AND I'D LIKE TO CALL
THE VIRTUAL MEETING TO ORDER.
THANK YOU FOR BEING HERE TODAY.
I WOULD FIRST LIKE TO WELCOME
OTHER MEMBERS OF THE NSABB, OUR
FEDERAL COLLEAGUES AND AGENCY
AND MEMBERS OF THE PUBLIC
JOINING ON WEBCAST TODAY.
AS THOSE OF YOU PARTICIPATING
KNOW, THE NSABB IS A FEDERAL
ADVISORY COMMITTEE THAT PROVIDES
REQUESTED ADVICE, GUIDANCE AND
RECOMMENDATIONS TO THE
U.S. GOVERNMENT ON BIO SECURITY
AND LIFE SCIENCE RESEARCH
CONCERNS.
BEFORE I MAKE ADDITIONAL
REMARKS, I'D LIKE TO TURN THE
AGENDA OVER TO CARI YOUNG THE
DESIGNATED FEDERAL OFFICER OF
NSABB TO REVIEW THE POLICY AND
PROVIDE ADDITIONAL REMINDERS.
CARI.
>> THANK YOU, I'LL BRIEFLY
DESCRIBE THE RULES OF CONDUCT
AND CONFLICT OF INTEREST
STATEMENT FOR THE NSABB.
AS A MEMBER OF THIS COMMITTEE
YOU'RE A SPECIAL GOVERNMENT
EMPLOYEE AND THEREFORE SUBJECT
TO RULES OF CONDUCT THAT APPLY
TO GOVERNMENT EMPLOYEES.
THE RULES AND REGULATIONS ARE
EXPLAINED IN A REPORT TITLED
STANDARDS OF ONLY OF ETHICAL
CONDUCT FOR EMPLOYEES OF THE
EXECUTIVE BRANCH.
YOU RECEIVE THE WHEN APPOINTED
TO THE COMMITTEE.
IN ADDITION TO REMINDING YOU
ABOUT THE IMPORTANCE OF
FOLLOWING THE ETHICS RULES, WE
ALWAYS LIKE TO REVIEW THE STEPS
WE TAKE AND ASK YOU TO TAKE TO
ENSURE THAT ANY CONFLICTS OF
INTEREST ARE ADDRESSED.
AS YOU KNOW, AT SCHEDULED
INTERVIEWS YOU PROVIDE US WITH
INFORMATION ABOUT YOUR PERSONAL,
PROFESSIONAL AND FINANCIAL
INTERESTS.
WE USE THIS INFORMATION AS THE
BASIS FOR ASSESSING WHETHER YOU
HAVE ANY REAL, POTENTIAL OR
APPARENT CONFLICTS OF INTEREST
THAT COULD COMPROMISE YOUR
ABILITY TO BE OBJECTIVE IN
GIVING ADVICE DURING COMMITTEE
MEETINGS.
WHILE WE WAIVE CONFLICTS OF
INTEREST FOR GENERAL MATTERS
BECAUSE WE BELIEVE YOUR ABILITY
TO BE OBJECTIVE WILL NOT BE
AFFECTED BY YOUR INTERESTS WE
RELY ON YOU TO BE ATTENTIVE TO
OF A POSSIBLE INTEREST AFFECTING
YOUR INTEREST AND ASK YOU TO
RECUSE YOURSELF AND LEAVE THE
ZOOM MEETING.
IF YOU HAVE ANY QUESTIONS ABOUT
RULES OF CONDUCT OR CONFLICT OF
INTEREST, OUR COMMITTEE
MANAGEMENT OFFICER, SONYA
FREEMAN WILL BE TRHAPPY TO ADDRS
THEM.
KEEP YOUR MIKES MUTED WHEN NOT
SPEAKING BEING AND TURN YOUR
CAMERAS ON WHEN SPEAKING AND USE
THE RAISED HAND FUNCTION IN ZOOM
AND USE THAT TO INDICATE YOUR
INTEREST IN JOINING THE
DISCUSSION AND DR. PARKER, I'LL
TURN IT OVER TO YOU.
>> THANK YOU, CARI.
BEFORE WE GET INTO THE MEAT OF
THE MEETING A FEW THINGS I WANT
TO SPEAK ABOUT AND ANNOUNCE.
FIRST I'D LIKE IT TAKE THE
OPPORTUNITY TO THANK THOSE NSABB
MEMBERS WHO HAVE COMPLETED THE
TERMS OF SERVICE SINCE THE BOARD
LAST MET AND SPECIFICALLY
DOCTORS PAMELA SILVER AND
DR. EAGAN PROVIDING EXPERTISE
AND THOUGHTFUL INPUT AS MEMBERS
AND I'D LIKE TO THANK THEM FOR
THEIR DEDICATED SERVICE.
I WOULD ALSO LIKE TO EXTEND A
WARM WELCOME TO THE INCOMING
VOTING MEMBERS AND SEVERAL
EX-OFFICIO MEMBERS JOINING FROM
ACROSS THE GOVERNMENT.
I'M GLAD AND ESPECIALLY PLEASED
TO SEE SO MANY WHY YOU
EX-OFFICIOS JOINING.
YOUR INPUT WILL BE INVALUABLE TO
THE BOARD GOING FORWARD.
THANK YOU FOR YOUR WILLINGNESS
TO SERVE AND SUPPORT THE NSABB
FOR IMPORTANT INFORMATION YOU'LL
BRING ACROSS THE AGENCY.
LASTLY, I'D LIKE TO ANNOUNCE MY
TERM OF SERVICE WOULD BE SERVING
AS A MEMBER AND CHAIR OF THE
NSABB WILL COME TO AN END AT THE
END OF THE MONTH.
THIS IS MY LAST MEETING.
I WANT TO SAY IT'S BEEN AN HONOR
TO SERVE WITH ALL THE NSABB
BOARD MEMBERS AND CURRENT
MEMBERS THAT CULMINATED IN OUR
2023 NSABB REPORT.
I KNOW THAT REPORT WAS WELL
RECEIVED IN MANY CIRCLES SO
THANK YOU FOR YOUR DEDICATION.
IT'S BEEN AN HONOR TO SERVE WITH
ALL OF YOU.
I WANT TO SAY A SPECIAL THANKS
TO CARI, KEVIN AND OTHER MEMBERS
OF THE STAFF WHO PROVIDED US
OUTSTANDING SUPPORT THROUGH OUR
DELIBERATIONS.
WE COULDN'T HAVE DONE THE WORK
AND PRODUCED THE REPORT WE DID
SO WELL RECEIVED WITHOUT THEIR
TIRELESS WORK BEHIND THE SCENES
IN SUPPORT OF US.
SO WITH THAT DONE, I AM
ESPECIALLY PLEASED RACHEL
LEVINSON WILL TAKE OVER STARTING
NEXT MONTH OF NSABB.
WE'VE HAD THE PLEASURE OF BEING
COLLEAGUES MANY YEARS INCLUDING
WORKING ON NSABB AND OTHER
RELATED ACTIVITIES.
I'M CONFIDENT SHE WILL BE A
STRONG AND EFFECTIVE LEADER TO
NSABB AND YOU WILL BENEFIT FROM
HER EXPERTISE AND LEADERSHIP.
YOU'RE IN GOOD HANDS WITH
RACHEL.
AND NOW AS WE BEGIN TO GET INTO
THE MEAT OF THE MEETING WE'RE
FORTUNATE TO BE JOINED BY
REPRESENTATIVES FROM THE
EXECUTIVE OFFICE OF THE
PRESIDENT AND DEPARTMENT OF
HEALTH AND HUMAN SERVICES TO
PROVIDER OPENING REMARKS AND
CONTEXT FOR THE WORK THE
COMMITTEE WILL BE TAKING ON
AFTER THIS MEETING.
SO TO GET US STARTED, I WOULD
LIKE TO WELCOME DR. SANDROM THE
SPECIAL ASSISTANT TO THE
PRESIDENT AND SENIOR DIRECTOR OF
GLOBAL HEALTH SECURITY AND BIO
DEFENSE AT THE NATIONAL SECURITY
COUNCIL.
HE SERVED AS THE DIRECTOR FOR
THE CENTER FOR BIO ENGINEERING
AT THE NATIONAL LABORATORY WHERE
HE LED THE LAB'S BIO
ENGINEERING, STRATEGY AND
TECHNOLOGY DEVELOPMENT
ACTIVITIES TO ADDRESS CRITICAL
CHALLENGES IN HEALTH AND BIO
SECURITY.
HE ALSO HAS EXPERIENCE IN THE
PRIVATE SECTOR LEADING EFFORTS
TO DEVELOP MODELLING AND
SOFTWARE FOR PHYSIOLOGY AND
BIOLOGY.
HIS EXTENSIVE AND VARIED
EXPERIENCES BRING A WEALTH OF
EXPERTISE AND WE LOOK FORWARD TO
HIS INSIGHT.
IT'S MY HONOR TO HAND THE
DISCUSSION OVER HIM.
>> I APPRECIATE IT.
THANK YOU ALL FOR JOINING AND TO
OUR COLLEAGUES OVER IN HHS FOR
SUPPORTING THIS PARTICULAR
ENDEAVOR AND KICKING THIS
MEETING OFF.
AT THE OUTSET I WANT TO CONVEY
MY PERSONAL THANKS AND GRATITUDE
TO THIS COMBHT COMMITTEE TO HE
FINALIZE THE GOVERNMENT
OVERSIGHT OF DUAL USE AND
PATHOGENS WITH ENHANCED PANDEMIC
POTENTIAL.
THE WORK FROM NSABB AND ITS
THOUGHTFUL RECOMMENDATIONS
DIRECTLY INFORMED THIS EFFORT TO
HELP UNIFY, STREAMLINE, EXPAND
AND STRENGTHEN THE DUAL USE OF
RESEARCH OF CONCERN.
THAT RECOGNIZES THE BENEFITS AND
RISKS ASSOCIATED WITH RESEARCH
ON PATHOGENS AND TOXIN.
THEY'RE CRITICAL TO STRENGTHEN
OUR BIO DIVERSE AND CALLED OUT
IN OUR STRATEGY AND CREATE
OVERSIGHT.
THE POLICY ALSO ACKNOWLEDGES THE
RAPIDLY EVOLVING NATURE OF
COMPUTATIONAL BIOLOGY AND
INCREASING USE OF INSILICO
MODELS AND DATA SETS INCLUDING
ARTIFICIAL INTELLIGENCE METHODS
AND APPROACHES TO BRING BIOLOGY
KNOWLEDGE, INFORMATION,
TECHNOLOGIES AND PRODUCTS.
BUT WHILE THE POLICY HAS
OVERSIGHT OF THE COMPUTATIONAL
TECHNOLOGIES AND DATA SET DOES
NOT HAVE CONSISTENT DATA
RESEARCH AND IN SILICO MODELS
CAN CREATE AN INFORMATION HAZARD
OR PROVIDE THE CAPABILITY TO
ENABLE MALACTORS AND ADVERSARIES
TO EVADE OUR PREPAREDNESS AND
CAUSE HARM.
AT THE SAME TIME WE UNDERSTAND
THE IN SILICO APPROACHES ARE
CRITICAL TO OUR MITIGATION
STRATEGY TO REDUCE THREATS FROM
BIOLOGICAL INCIDENTS.
FOR INSTANCE, OF COURSE IN
SILICO APPROACHES OFFER I SAFER
WAY TO STUDY BIOLOGY WITHOUT
EXPERIMENTATION AND THE
POTENTIAL RISK FROM ACCIDENTS.
THEY'RE CRITICAL TO HELPING
DEVELOP MORE RAPIDLY MORE
EFFECTIVE COUNTER MEASURES
AGAINST EVOLVING BIO THREATS.
REALIZING THE ENORMOUS PROMISE
OF THESE TECHNOLOGIES, AND UNDER
SCORING OUR EFFORTS FOR
LEADERSHIP IS A KEY PRIORITY OF
THIS ADMINISTRATION.
AS SUCH WE ARE REQUESTING THE
NSABB PERFORM A DETAILED REVIEW
AND PROVIDE RECOMMENDATIONS ON
HOW TO BEST IDENTIFY,
PRIORITIZE, PREVENT AND MITIGATE
RISKS FROM MISUSE OF INSILICO,
RESEARCH, MODELS, TOOLS AN DATA
SETS.
WE HOPE THIS COMMITTEE WILL
CONSIDER WAYS IN WHICH INSILICO
RESEARCH ONLY PATHOGENS AND
TOXINS COULD CREATE INFORMATION
HAZARDS THAT COULD BE EXPLOITED
BY NEFARIOUS ACTORS OR CREATE
NEW BIO WEAPONS.
WE HOPE TO HAVE A SECURITY
INFORMED SET OF RECOMMENDATIONS
ON FUTURE POLICY INCLUDING
SPECIFIC REVIEW CRITERIA,
GUIDELINES AND BEST PRACTICES
FOR RESEARCHERS AND SUGGESTIONS
FOR SEQUENCEFUL ORIENTATION.
ONCE AGAIN THANK YOU FOR
UNDERTAKING THIS CRITICAL EFFORT
AND WE LOOK FORWARD TO READING
YOUR REPORT.
THANK YOU.
>> THANK YOU FOR YOUR ENGAGING
AND THOUGHT PROVOKING REMARKS AS
THE BOARD BEGINS TO TAKE ON THIS
NEW TASK THAT WE'LL GET IN A FEW
MINUTES.
FIRST, NEXT WELCOME PLEASED TO
WELCOME DR. SOMA AS THE
ASSISTANT DIRECTOR FOR
ARTIFICIAL INTELLIGENCE AND BIO
SECURITY IN THE WHITE HOUSE
OFFICE OF SCIENCE AND TECHNOLOGY
POLICY.
BEFORE JOINING OSTP HE WAS
PROGRAM MANAGER AT DARPA WHERE
HE EVERY SAW RESEARCH IN BIO
ELECTRONICS, BRAIN COMPUTER
INTERFACES AND BIO SECURITY.
PRIOR TO THAT WORK HE WAS A
PHYSICIAN SCIENTIST AT THE BROD
INSTITUTE AND HARVARD AND HE
WILL PROVIDE PERSPECTIVE TO THE
BOARD.
PLEASE GO AHEAD.
>> THANK YOU SO MUCH FOR THE
INTRODUCTION.
THANK YOU FOR JOINING TODAY.
I'LL KEEP MY REMARKS BRIEF TO
MOVE TO DO DISCUSSION.
FIRST I'D LIKE TO ACKNOWLEDGE
HHS AND KICKING THIS OFF.
ON BEHALF OF THE OSTP I'D LIKE
TO REITERATE WE'RE LOOKING AT
THE ACCIDENTAL AND BIO THREATS
AND GRATEFUL FOR THE
RECOMMENDATIONS THE NSABB
PROVIDED THAT SHAPED THE
DUAL-USE RESEARCH POLICY AND
EAGER TO SEE CONTINUED
ENGAGEMENT SO WE CAN BETTER
UNDERSTAND HOW TO EXTEND THIS
POLICY TO THE IN SILICO REGIME
DUE TO THE VARIETY OF REASONS
HIGHLIGHTED.
I WANT TO THANK YOU AGAIN AND
VERY MUCH LOOK FORWARD TO
READING YOUR REPORT.
>> THANK YOU, DR. SARMA.
NOW I'D LIKE TO WELCOME MS. ELAY
FLA BUSH THE DEPUTY SECRETARY
FOR THE OFFICE OF THE ASSISTANT
SECRETARY FOR PLANNING AND
EVALUATION AT HHS AND BRINGS 30
YEARS OF EXPERIENCE WORKING FOR
THE DEPARTMENT OF HHSED AND HAS
EXPERTISE IN POLICY DEVELOPMENT,
ANALYSIS AND EVALUATION AND
PLANNING RELATED TO SCIENCE AND
DATA POLICY ISSUES AND BRINGS
UNIQUE PERSPECTIVE FOR THE DATA
DRIVEN AND SCIENTIFICALLY
INFORMED APPROACH.
MS. BUSH, THE FLOOR IS YOURS.
>> THANK YOU FOR THE KIND
INTRODUCTION AND ON BEHALF OF
THE DEPARTMENT OF HEALTH AND
HUMAN SERVICE THANK YOU FOR THIS
YOUR SERVICE ON THIS FEDERAL
ADVISORY COMMITTEE AND I'D LIKE
TO THANK MY NIH COLLEAGUES FOR
THEIR MANAGEMENT OF THE
COMMITTEE AND HOSTING THE
MEETING AND THE OFFICES OF
SCIENCE AND TECHNOLOGY POLICY
FOR THEIR OPENING REMARKS.
IN COORDINATION WITH
U.S. GOVERNMENT PARTNERS, HHS IS
COMMITTED TO ENABLING CRITICAL
LIFE SAVING ADVANCES IN SCIENCE
AND TECHNOLOGY WHILE
APPROPRIATELY MITIGATING RISKS.
SOME OF THE CRITICAL RESEARCH
THAT HHS SUPPORTS HELPS US
UNDERSTAND THE NATURE OF
PATHOGENS AND EFFORTS THROUGH
DEVELOPMENT OF VACCINES AND
OTHER MEDICAL COUNTER MEASURES.
I'M PROUD TO SAY HHS HOUSES AND
FUNDS THE WORLD'S LEADING
EXPERTS ON TOPICS FROM SYNTHETIC
BIOLOGY AND DEVELOPMENTS AND
SAFETY EFFORTS AND MANY EXPERTS
IN THE MEETING NOW.
WE'RE LIVING IN AN EXCITING TIME
WHERE WE ARE LEARNING EVERY DAY
THE MANY WAYS IN WHICH
ARTIFICIAL INTELLIGENCE WILL
IMPROVE HUMAN HEALTH AND HEALTH
CARE DELIVERY THOUGH WE KNOW THE
ADVANCES COME WITH POTENTIAL
RISK AND NEED POLICY AND
GUIDANCE THAT PROMOTE SAFETY AND
SECURITY IN EQUAL MEASURE.
WITH THAT GOAL IN MIND, HHS
DEVELOPED A ROBUST SYSTEM OF
POLICIES AND PRACTICES THAT
GUIDE STAKEHOLDERS ACROSS THE
BIO MEDICAL AND RESEARCH ECO
SYSTEM.
THESE INCLUDE POLICIES TO
PROTECT RESEARCH PARTICIPANTS,
ENCOURAGE SHARING AND SHAPE THE
PRIVACY OF HEALTH INFORMATION
AND OF COURSE MITIGATE BIO
SECURITY CONCERNS.
WHILE A.I. MAY NOT BE EXPLICITLY
MENTIONED IN EVERY POLICY, HHS'S
POLICY FRAMEWORK IS DESIGN TO
RESPONSIBLY GUIDE AND GOVERN
ADVANCING SCIENCE AND EMERGING
TECHNOLOGIES INCLUDING
DEVELOPMENT AND USE OF A.I.
TECHNOLOGIES IN RESEARCH.
THAT IS EXACTLY WHY WE'VE BEEN
WORKING WITH PARTNERS ACROSS THE
GOVERNMENT INCLUDING MY
CO-PRESENTERS TODAY ON THE SAFE,
SECURE AND TRUSTWORTHY
DEVELOPMENT AND USE OF
ARTIFICIAL INTELLIGENCE.
ON THE 2024 FRAMEWORK FOR
NUCLEIC SYNTHESIS SCREENING AND
DUAL USE RESEARCH OF CONCERN AND
PATHOGENS WITH ENHANCED PANDEMIC
POTENTIAL.
THE PARTNERSHIP WE'VE HAD AT THE
USG HAS ALLOWED US TO BALANCE
THE RISK IN RESEARCH WITH THE
BENEFITS TO EMERGING
TECHNOLOGIES.
FOR EXAMPLE, CDC IS USING
ARTIFICIAL INTELLIGENCE AND
MACHINE LEARNING TO ACCELERATE
RESPONSE TO LEGIONAIR'S DISEASE.
AND WE'RE CONTINUING TO ASSESS
THE DEVELOPMENT OF DRUG AND
BIOLOGICAL PRODUCTS IN DRUG
MANUFACTURING AND IDENTIFYING
SAFETY ISSUES AND NIH IS
PILOTING TRIAL GPT A FIRST OF
ITS KIND LARGE LANGUAGE MODEL
FRAMEWORK TO ASSIST IN MATCHING
PATIENTS TO TRIALS.
THROUGHOUT WE CONTINUE TO FOSTER
SOUND, SUSTAIN ADVANCED IN THE
SCIENCES UNDERLYING MEDICINE,
PUBLIC HEALTH AND SOCIAL
SERVICES WHILE MAKING SURE THE
GUARDRAILS ARE IN PLACE FOR
RESPONSIBLE, EQUITABLE AND SAFE
USE.
TECHNOLOGY IS CONSTANTLY
EVOLVING AND HHS, INCLUDING NIH
WILL STAY NIMBLE AND MINIMIZE
RISK.
THIS COMMITTEE IS CRITICAL TO
PROVIDE ADVICE ON ISSUES RELATED
TO BIO SAFETY AND SECURITY AND
WE THANK YOU IN ADVANCE FOR YOUR
WORK CONSIDERING THESE CRITICAL
ISSUES.
BACK TO YOU, GERRY.
>> I WANT TO THANK ALL FOLKS
FROM THE WHITE HOUSE AND HHS FOR
PROVIDING OPENING REMARKS AND
THE WORK YOU'RE ABOUT TO RECEIVE
IS IMPORTANT TO THE WHITE HOUSE
AND HHS.
IT'S MY HONOR TO TURN IT OVER TO
DR. TABAK AND JORGENSON FROM THE
NATIONAL INSTITUTES OF HEALTH TO
DELIVER THE CHARGE TO THE BOARD.
DR. TABAK.
>> THANK YOU, GERRY FOR THE
INTRODUCTION.
AND I CERTAINLY APPRECIATE THE
COMMENTS FROM OUR WHITE HOUSE
AND HHS COLLEAGUES ON THIS
IMPORTANT TOPIC.
I'M LARRY TABAK THE PRINCIPAL
DEPUTY DIRECTOR FROM NIH AND
JOINED BY DR. LYRIC JORGENSON
THE NIH ASSOCIATE DIRECTOR FOR
SCIENCE POLICY AND WISH TO
EXTEND A WARM WELCOME TO ALL OF
YOU AND THANK YOU FOR JOINING
THE DISCUSSION AROUND THE NEW
CHARGE.
JUST BEFORE WE MOVE TO THE MAIN
PRESENTATION, LET ME ECHO GERRY
AND GIVE MY THANKS TO THE ENTIRE
COMMITTEE AND WELCOMING NEW
MEMBERS AN THOSE VOTING AND
EX-OFFICIO AND MY THANKS TO PAM
AND SILVIA WHO COMPLETED THEIR
SERVICE LAST SUMMER AND IT JOHN
GABBENSTEIN ROLLING OFF AT THE
END OF THIS MONTH.
EACH WE'RE GRATEFUL FOR THEIR
SERVICE AND CRITICAL INSIGHTS.
AND FINALLY NO WORDS TO THANK
YOU, GERRY, SUFFICIENTLY.
HE'S COMPLETING HIS TERM AT THE
END OF THE MONTH.
YOUR DEDICATION AS CHAIR OF THE
NSABB HAS BEEN EXTRAORDINARY AND
ON BEHALF OF NIH, HHS WE ARE SO
VERY VERY GRATEFUL FOR ALL
YOU'VE DONE TO LEAD THIS
COMMITTEE AND THE INCREDIBLE AND
IMPORTANT IMPACTFUL WORK THAT
YOU HAVE LAID OUT SO THANK YOU.
>> IT'S BEEN AN HONOR TO SERVE,
THANK YOU.
>> RACHEL, THANK YOU FOR YOUR
WILLINGNESS TO PICK UP THE
MANTLE AS CHAIR OF THIS NSABB
AND NOW I'LL DRAW YOUR ATTENTION
TO THE SLIDE BEING DISPLAYED.
LET ME SET THE STAGE FOR ALL
TUNING IN WITH A QUICK RECAP OF
WHAT THIS GROUP HAS ACCOMPLISHED
OVER THE PAST FEW YEARS.
ALL OF YOU ARE AWARE THAT LIFE
SCIENCES INCLUDING STUDIES THAT
AIM TO UNDERSTAND RAPIDLY
EVOLVING PATHENS AN RELATED
TESTING AND COUNTER MEASURES
HAVE IMPORTANT BENEFITS AND ALSO
RISKS.
AND NIH, HHS AND THE
U.S. GOVERNMENT AS A WHOLE
REMAIN COMMITTED TO ENSURING
RESEARCH ON INFECTIOUS AGENTS IS
CONDUCTED RESPONSIBLY IN A
MANNER THAT CONSIDERS THE
POTENTIAL BIO SECURITY AND BIO
SAFETY RISKS.
NSABB MEMBERS ARE RECOGNIZED
EXPERTS IN THEIR RESPECTIVE
FIELDS AND THEY ARE HELP THE
U.S. GOVERNMENT NAVIGATE VERY
IMPORTANT QUESTIONS ABOUT SAFETY
AND SECURITY, WHICH ALLOW US TO
PRESERVE THE BENEFITS AND TO
MITIGATE THE POTENTIAL RISKS.
FOR THE LAST NSABB CHARGE WE
REQUESTED MEMBERS TO REVIEW USG
POLICIES RELATED TO HIGHER RISK
WORK WITH PATHOGENS AND THE
RECOMMENDATIONS WE'VE ALLUDED TO
OUTLINED PROPOSED BIO SECURITY
FRAMEWORK FOR THE FUTURE OF
SCIENCE AS WELL AS INPUTS FROM
THE PUBLIC WERE INSTRUMENTAL IN
INFORMING THE DEVELOPMENT OF THE
RECENTLY RELEASED USG POLICY FOR
OVERSIGHT OF DUAL USE RESEARCH
OF CONCERN AND PATHOGENS WITH
ENHANCED PANDEMIC POTENTIAL
WHICH IS SOMETIMES REFERRED TO
AS THE DIRK-PEP POLICY.
THIS POLICY ISSUED IN MAY OF
2024 AND EFFECTIVE IN MAY OF
2025 CREATES A UNIFIED FEDERAL
OVERSIGHT FRAMEWORK THAT
ADDRESSES OVERSIGHT OF RESEARCH
ON BIOLOGICAL AGENTS AND TOXINS
THAT WHEN ENHANCED HAVE THE
POTENTIAL TO POSE RISK TO PUBLIC
HEALTH, AGRICULTURE, FOOD
SAFETY, ECONOMIC SECURITY OR
NATIONAL SECURITY.
WE'RE SO VERY GRATEFUL TO THE
NSABB FOR CRITICAL GUIDANCE IN
FORMING THE POLICY AND WE WANT
TO POINT TO THOSE WATCHING TODAY
TO THE LINK SHOWN AT THE BOTTOM
THEY'RE INTERESTED IN ADDITIONAL
INFORMATION.
IF WE HAVE THE NEXT SLIDE,
PLEASE.
SO, THE POLICY LOOKS AT BIOLOGY
AND INCREASING USE OF
COMPUTATIONAL MODELS AND
APPROACHES INCLUDING ARTIFICIAL
INTELLIGENCE THAT PLAY MAY
PRODUCTION TO THE DUAL-USE
BIOLOGIC INFORMATION AND
TECHNOLOGY AND PRODUCTS.
AS MANY ARE AWARE THERE'S
EXTENSIVE DISCUSSIONS AND
COORDINATED ACTS ACROSS THE
U.S. GOVERNMENT IN RESPONSE TO
THE RAPID EVOLUTION OF IN SILICO
APPROACHES INCLUDING ARTIFICIAL
INTELLIGENCE.
THIS HAS LEAD TO A SUITE OF
INNOVATION WHILE PROTECTING
PUBLIC SAFETY AND NATIONAL
SECURITY.
I'D LIKE TO HIGHLIGHT A FEW
RECENT AND ONGOING EFFORTS THAT
RELATE TO THE NSABB'S PURVIEW TO
HELP SET THE STAGE FOR TODAY'S
CHARGE.
IN 2023 PRESIDENT BIDEN SIGNED
EXECUTIVE ORDER 14110 ON SAFE,
SECURITY AND TRUSTWORTHY
DEVELOPMENT AND USE OF
ARTIFICIAL INTELLIGENCE
PROVIDING A STRATEGY TO HARNESS
POTENTIAL BENEFITS FROM A.I.
WHILE MITIGATING RISKS.
AND THERE WERE SEVERAL OUTPUTS
RELEVANT TODAY.
FIRST, A NATIONAL SECURITY MEMO
WAS RELEASED TO PROVIDE FURTHER
DIRECTION ON HARNESSING A.I.
MODELS AND A.I. ENABLED
TECHNOLOGIES.
THIS INCLUDE CONSIDERATIONS TO
RESEARCH USING A.I.
AT THE OUTSET SAFEGUARDS WERE
NEEDED TO ENSURE IN SILICO
RESEARCH WITH DUEL-USE
IMPLICATIONS WERE MANAGED AND
CONTROLLED TO THE NATIONAL
ACADEMIES CONSENSUS STUDY IS
UNDERWAY ON ASSESSING AND
NAVIGATING BIO SECURITY CONCERNS
AND BENEFITS OF ARTIFICIAL
INTELLIGENCE USE IN THE LIFE
SCIENC
SCIENCES WE KNOW THERE'S A NEED
TO MITIGATE CERTAIN BIO SECURITY
CHALLENGES WITH THE USE OF A.I.
AND WITH THE USE OF SYNTHETIC
NUCLEIC ACIDS AND WE'RE EXCITED
ABOUT THE POTENTIAL OF A.I.
MODELS AND HELPING US UNDERSTAND
THE STRUCTURE AND FUNCTION OF
BIO MOLECULES.
BUT OF COURSE THERE IS CONCERN
THIS TECHNOLOGY MAY MAKE IT
EASIER TO DESIGN AND GENERATE
NEW PATHOGENS OR TOXINS.
TO LIMIT THIS POTENTIAL,
U.S. GOVERNMENT AGENCIES HAVE
DEVELOPED A FRAMEWORK WHERE
SYNTHETIC NUCLEIC ACID SCREENING
FOR SEQUENCES OF CONCERN THAT
ESTABLISH REQUIREMENTS THAT
FEDERALLY FUNDED RESEARCHERS
MUST ORDER FROM PROVIDERS THAT
FOLLOW THIS FRAMEWORK.
AND BEFORE IN SILICO MODELLING
IS COMPLETED AND DATA SETS
AVAILABLE IT'S CRITICAL TO
SAFEGUARD AGAINST ANYTHING THAT
COULD LEAD TO BIO SECURITY RISK.
WITH THIS IN MIND THE NATIONAL
ACADEMIES IS PLANNING A WORKSHOP
OF IN SILICO IN SILICO AND
APPROACH OF BIOLOGICAL AGENTS
AND ORGANISMS AND WE LOOK
FORWARD TO THAT WORKSHOP REPORT
IN 2025.
WHAT IS NEXT?
THOUGH MUCH PROGRESS HAS BEEN
MADE WE NEED A MORE GRANULAR
RHODE ISLAND -- RODE MAPPING
AND DEVELOPED THE NEXT CHARGE
BASED ON THREE HIGH-LEVEL ISSUES
THAT BUILD ON THE 2024 DIRK PAP
POLICY AND PREVIOUS NSABB
RECOMMENDATIONS.
FIRST, WE THINK THERE'S MORE TO
BE DONE TO IDENTIFY AND ASSESS
THE RISK OF MODELS WITH DUAL USE
POTENTIAL FOR CONDUCTING
RESEARCH THROUGH COMPUTATIONAL
ATTORNEY GE
STRATEGIES THAT MAKE THE NOVEL
BIOLOGICAL AGENT OR TOXIN MORE
ACCESSIBLE.
AND AFTER IDENTIFYING THE RISK
AND BENEFITS WE NEED GUIDANCE
FOR RISK MITIGATION TO
STRENGTHEN SAFETY AND BOLSTER
THE TRUSTWORTHINESS OF THIS
RESEARCH AND FINALLY METHODS TO
RESPONSIBLY COMMUNICATE PRODUCTS
AND RESEARCH THE COMMUNITY ON
POTENTIAL MISUSE, RISKS AND
MITIGATION STRATEGIES.
IF I MAY HAVE THE NEXT SLIDE.
THAT BRINGS US TO OUR CHARGE FOR
THE NSABB COMMITTEE TODAY.
BASED ON THESE HIGH-LEVEL NEEDS
I'VE OUTLINED WE HAVE SPLIT THE
CHARGE INTO THREE PARTS AND WE
HAVE DELINEATED THEM INTO TWO
PHASE TO PROMPT DISCUSSION ON
THE TIME LINE FOR THE WORK.
PHASE 1 HAS TWO MAJOR DON'TS.
THIS FIRST, 1A IS CENTERED ON
IDENTIFYING AND ASSESSING RISKS
AND BENEFITS.
WE ASK THE NSABB TO RECOMMEND
STRATEGIES FOR IDENTIFYING AND
OPTIONS FOR MITIGATING POTENTIAL
RISKS ASSOCIATED WITH IN SILICO
RESEARCH, COMPUTATIONAL MODELS
INCLUDING A.I. MODELS AND DATA
SETS AND LIFE SCIENCE SETTINGS.
THIS INCLUDES IDENTIFYING
APPROACHES, ABILITY AND
PROPENSITY OF MODELS THAT COULD
RESULT IN THE DEVELOPMENT OF
DUAL USE INFORMATION OR MODELS
DIRECTLY ENABLING THE DESIGN OF
A PATHOGEN WITH ENHANCED
PANDEMIC POTENTIAL OR NOVEL B
BIOLOGIC AGENT OR TOXIN AND
ASSESSING THESE RISKS AGAINST
YEAR CRITERIA AND PUBLISHING
RISK RESULTS AN HOW IN SILICO
RESEARCH CAN AID IN THE DESIGN,
DEVELOPMENT, ENHANCEMENT OR
ACQUISITION OF TRANSMISSIBLE
BIOLOGICAL AGENTS WITH SPECIFIC
ATTRIBUTES.
THIS IS THE SECOND PHASE, PHASE
1B.
THIS COULD BE DONE IN CONCERT
WITH PHASE 1A LOOKING AT
STRATEGIES WHILE DEFINING
BENEFITS AND RISK OF RESEARCH.
HERE WE CHARGE THE NSABB TO
OUTLINE OPTIONS INCLUDING
METHODS AND APPROACHES TO
INCORPORATE CURRENT FUTURE
GUIDELINES AND STANDARDS FOR
RISKS OF DUAL USE, MODELS
DEVELOPED BY THE STANDARDS OF
INFORMATION AND TECHNOLOGY TO
THE DEVELOPMENT AND RELEASE OF
DUAL-USE A.I. MODELS, DATA SETS
AND RESEARCH RESULTS.
SECOND TO MITIGATE THE RISK OF
MISUSE OF DEPLOYED MODELS AND
API LEVEL SAFEGUARDS AND
CUSTOMER PRACTICES THAT COULD
IDENTIFY POTENTIAL CASES OF
MISUSE WITH MINIMAL DISRUPTION
TO LEGITIMATE USERS AND TO
SELECT THE APPROPRIATE
MITIGATION STRATEGIES THAT ARE
COMMENSURATE TO THE POTENTIAL
RISK AND BENEFIT OF THE DUAL USE
A.I. MODEL OF DATA SETS.
IF I MAY HAVE THE NEXT SLIDE.
THIS TRAAKES US TO THE SECOND
PHASE OF THE EFFORT AND CHARGE
THE NSABB TO DELINEATE
RESPONSIBLE METHODS IN THE
SECOND EFFORT AND EXPLORE
OPTIONS INCLUDING METHODS AND
APPROACHES TO RESPONSIBLY SHARE
AND COMMUNICATE RESEARCH RESULTS
IN DATA SETS IN REPOSITORIES AND
PREPRINTS AND PEER-REVIEWED
PUBLICATIONS INCLUDING DECISIONS
AND STRUCTURED ACCESS PARADIGMS
FOR HOSTING DUAL-USE MODELS AND
DATA SETS.
AND WANT TO EDUCATE THE
SCIENTIFIC COMMUNITY AND ENHANCE
INSTITUTIONAL AWARENESS AND
OVERSIGHT OF THE POTENTIAL
MISUSE, RISKS AND MITIGATION
STRATEGIES.
GIVEN THE GREAT IMPORTANCE OF
THIS TOPIC WE ARE PROPOSING THE
BOARD WORK ON AN EXPEDITED TIME
LINE WRAPPING UP BY THE END OF
2025.
HOW YOU APPROACH THE CHARGE IS
UP TO THE COMMITTEE BUT YOU SEE
DISPLAYED A TIME LINE TO START
THE DISCUSSION AND HAVE A
WORKING GROUP TO ADDRESS THE
CHARGE AND BRING IN INDIVIDUALS
WITH RELEVANT EXPERTISE.
OF COURSE THE WORKING GROUP WILL
BENEFIT FROM UNDERSTANDING
EXPERT AT THE LEADING EDGE OF
THE IN SILICO RESEARCH EFFORTS
AND COMPUTATIONAL MODELS
INCLUDING A.I. AND DATA SETS AND
LIFE SCIENCE SETTINGS.
OTHERS WHO HAVE BEEN THINKING
DEEPLY HOW TO EVALUATE AND
MITIGATE RISK AND THOSE WITH
REAL STRONG UNDERSTANDING OF THE
EVOLVING BIO SECURITY AND
ETHICAL, LEGAL AND SOCIAL
IMPLICATIONS OF SUCH RESEARCH.
THIS WORKING GROUP SHOULD KICK
OFF WE HOPE BY JANUARY OF 2025.
ALONG THE WAY WE HOPE THE
WORKING GROUP WILL BE INFORMED
BY CONCURRENT EFFORTS SUCH AS
THE ACADEMIES' EFFORTS AND INPUT
FROM THE PUBLIC AND SUBJECT
MATTER EXPERTS.
WE ASK THE NSABB REPORT OUT IN
TWO WAYS.
FIRST, BY PROVIDING AN INTERIM
REPORT IN THE SUMMER OF 2025 AND
SECOND BY DECEMBER OF 2025
PROVIDING RECOMMENDATIONS AND A
FINAL RECORD INCLUDING FINDINGS
AND STRATEGIES TO INFORM FUTURE
U.S. GOVERNMENT DISCUSSION
REGARDING OUR OVERSIGHT
FRAMEWORKS AND PRACTICES AROUND
IN SILICO RESEARCH AND
COMPUTATIONAL MODELS WITH
POTENTIAL DATA SECURITY RISK AND
ULTIMATELY ENSURING SAFETY AND
MINIMIZING RISK TO PUBLIC
HEALTH.
WE APPRECIATE THIS IS GOING TO
BE A LIFT -- WE ONLY WOULD TO
PEOPLE NOT BUSY -- NO, WE KNOW
HOW BUSY YOU ARE BUT YOU HAVE
EXPERTISE IN THESE ISSUES AND
WITH THAT I'LL TURN IT TO GERRY
FOR NSABB MEMBER DISCUSSION
REGARDING THE CHARGE AND WE
CERTAINLY LOOK FORWARD TO THE
CONVERSATION.
GERRY.
>> THANK YOU, DR. TABAK.
THANK YOU FOR THE EXCELLENT
PRESENTATION.
IT'S A TIMELY CHARGE AND YES,
THE TIME LINES ARE AGGRESSIVE
BUT I THINK THE ISSUES DEMAND
THE BOARD APPROACH THIS
AGGRESSIVE TIME LINE IN A
SERIOUS AND THOUGHTFUL MANNER.
MAYBE THAT'S EASY FOR MANY TO
SAY SINCE I'M GOING OFF THE
BOARD BUT NONETHELESS IT'S A
TIMELY CHARGE AND KNOW THE BOARD
IS READY TO GO BACK TO WORK.
WITH THAT I WANT IT TURN TO MY
MEMBERS OF NSABB IF YOU HAVE
IMMEDIATE QUESTIONS OR IF
THERE'S QUESTIONS ON THE CHARGE
ON THE PROCESS YOU'LL BE
DEVELOPING AS YOU THINK ABOUT
MOVING FORWARD.
AND OF COURSE THERE'LL BE
WORKING GROUPS ESTABLISHED VERY
SOON JANUARY 2025 IS COMING UP
QUICK.
THOSE WILL BE FORMING AND I'M
SURE YOU'LL HAVE AN OPPORTUNITY
TO SHAPE THE PATH FORWARD TO
BEAT THE AGGRESSIVE TIME LINE.
>> THERE WERE TWO BIG STUDIES
BEING DONE THERE WAS ONE AT THE
NATIONAL ACADEMY AND --
>> ANOTHER ONE IS BEING DONE
WITH NSF AROUND RESPONSIBLE
PUBLICATIONS.
>> WE AT THE NSF WORKSHOP WILL
BE IN EARLY AND THEY'LL BE
DEVELOPING PROCEEDINGS OF THE
WORKSHOP FOLLOWING THAT.
>> WE MADE SURE THE FINDINGS YOU
ARE INFORMED SO THERE'S SYNERGY
ACROSS THE EFFORT.
>> INTRODUCE THE WORKING GROUP
TO THOSE AND CERTAINLY HAVE THEM
BRIEF WHAT THEY'RE DOING AND
ALSO THAT'S A GREAT IDEA TO BE
ABLE TO ATTEND OTHER MEETINGS.
>> THANK YOU ALL FOR PROVIDING
THE UPDATED CHARGE.
IT'S REALLY IMPORTANT AS WAS
JUST SHARED.
MY QUESTION IS REALLY MORE
RELATED TO THE PRIVATE SECTOR.
SO MUCH OF THIS RESEARCH IS
BEING DONE IN THE PRIVATE
SECTOR.
AS WE DEVELOP THE
RECOMMENDATIONS AND HOPING
LOOKING AT THE IMPLEMENTATION
WHAT ARE THE THOUGHTS OF THE
PRIVATE SECTOR AND HOW CAN WE
ENSURE THAT THESE ARE ALSO
ADOPTED BY THAT PARTICULAR
SECTOR SINCE IT'S SO LARGE AND
MUCH OF THE RESEARCH IS BEING
DONE THERE.
>> IT'S VERY IMPORTANT.
>> AS THE MEMBERS THINK ABOUT
THIS AND THINK OF THE START-UP I
CHALLENGE YOU TO THINK ABOUT THE
STAKE HOLDERS YOU WANT TO BRING
IN AND HEAR FROM AND GET THEIR
THOUGHTS ON THE IMPACT TO THE
PRIVATE SECTOR AND HOW TO BE
ENGAGED FROM THE START WILL BE
IMPORTANT, I THINK.
>> AND THIS IS SOMETHING THAT WE
ACROSS THE ENTIRETIY OF
GOVERNMENT HAVE BEEN THINKING
ABOUT.
YOU'VE SEEN RECENT PUBLICATIONS
FROM COLLEAGUES REGARDING
SYNTHETIC BIOLOGY AND
PROCUREMENT STANDARDS AND HHS IS
WORKING CLOSELY IN THE MODELS
WITH PRIVATE SECTOR ACROSS
GENERATIVE AND MULTIMODAL A.I.
AND HAVE MEANINGFUL
PARTICIPATION BY THE PRIVATE
SECTOR AND OTHERS AND THERE'SA
MODEL AND HOPE THE FUNDING IS
MOVING TOWARDS THE BEST
PRACTICES AND STANDARDS.
>> RACHEL.
>> TO GIVE GERRY A THANKS FOR
THE NOTE OF CONFIDENCE AND HHS
IN ALLOWING ME TO TAKE THIS
POSITION.
TO THE POINT THAT WAS JUST MADE
ABOUT THE PRIVATE SECTOR, I JUST
CAME FROM A MEETING OF PEOPLE
TALKING ABOUT THE APPLICATIONS
OF A.I. IN HEALTH AND THE ROLE
THE FEDERAL GOVERNMENT IN
OVERSEEING THOSE AND SEEING WHAT
ACTIVITIES ARE UNDERWAY.
IT'S CLEAR THAT THE PRIVATE
SECTOR DOES HAVE TO BE ENGAGED
IN THIS.
OUR MANDATE OF COURSE AS JUST
OUTLINED BY DR. TABAK IS BROAD
AND INCLUDES THAT BUT WE ARE
REALLY FOCUSSING ON THE ELEMENTS
OF BIO SECURITY IN THIS AND
UNDERSTANDING WHAT THE RISK AND
POTENTIAL ADVANTAGES ARE TO THE
APPLICATIONS OF A.I. IN RESEARCH
VERY BROADLY DEFINED.
SO I JUST WANT TO NOTE THAT AND
SAY THAT THE SUPPORT AND
INFORMATION THAT'S BEEN PROVIDED
ALREADY BY THE PEOPLE AT NASF
WHICH ARE INCREDIBLE AND IN
FOLLOWING GERRY'S LARGE FOOT
STEPS LEADING THE CHARGE IN WHO
COMPLEX CHARGES AND HOW THEY CAN
BE CARRIED OUT BUT I HAVE FULL
CONFIDENCE IN THE MEMBERS OF THE
NSABB TO ADDRESS THOSE AS WAS
POINT THE OUT THEY'RE VERY BUSY
PEOPLE BUT IN ROLES I THINK THAT
WILL ALLOW US TO CONTRIBUTE IN A
SUBSTANTIAL WAY IN THIS TASK.
>> RACHEL, I TOTALLY AGREE.
I HAVE FULL CONFIDENCE.
IT'S AN AGGRESSIVE TASK BUT IT'S
NEED ED AND TIMELY AND HAVE
CONFIDENCE IN YOUR LEADERSHIP
RAND EXPERTISE TO LEAD THE GROUP
THROUGH THIS SO THANK YOU FOR
TAKING ON THIS LEADERSHIP ROLE.
>> ANY OTHER QUESTIONS?
>> NO HANDS RIGHT NOW.
>> I WANT TO ASK THE MEMBER TO
THINK ABOUT WHO DO YOU WANT TO
HEAR FROM AND WHO DO YOU HAVE TO
HEAR FROM AND THAT WILL BE
SOMETHING THAT WILL BE SOME OF
YOUR FIRST CONVERSATIONS LOOKING
BACK TO WHERE WE BEGAN THE
CHARGE FOR OUR 2023 REPORT THAT
WAS ONE OF THIS FIRST THINGS I
RECALL DOING IS THINKING ABOUT
WHO WE MUST HEAR FROM AND HOW TO
DO THAT.
AND YOU WILL AS MEMBERS WILL
HAVE A WAY TO MOVE FORWARD IN
THE AGGRESSIVE TIME LINE AND
NEED TO HIT THE GROUND GROUND
RUNNING IN JANUARY 2025.
>> ANY OTHER FINAL THOUGHTS
BEFORE WE COME TO THE CLOSING OF
THE MEETING?
ANY OTHER FINAL HAND OR COMMENTS
FROM MEMBERS?
CARI, AM I MISSING ANYTHING
BEFORE WE GO TO CLOSING
COMMENTS?
>> NOTHING FROM ME.
DR. TABAK, DR. JORGENSON?
>> NO, THANK YOU.
>> RACHEL?
WELL --
>> LOOKING FORWARD TO THIS
AGGRESSIVE TIMETABLE AND I THINK
THE INFORMATION THAT WE'VE BEEN
GIVEN IS VERY WELL SUBSTANTIATED
WITH WHICH THE SCIENCE AND
TECHNOLOGY IS MOVING FORWARD AND
THE NEED FOR US TO MOVE FORWARD.
>> WITH THAT I'M GOING TO GO
AHEAD AND BEGIN TO WRAP UP THE
MEETING.
SO, AS WE'VE ALL HEARD TODAY THE
NSABB IS A VERY CRITICAL VOICE
IN THESE CONVERSATIONS AND THE
INPUT WE'VE DONE HAS BEEN PUT TO
GOOD USE AND HAS INFORMED
U.S. GOVERNMENT POLICIES IN
THINKING ON THIS AND I NOTICED
THE NEXT CHARGE YOU'LL BE
WORKING ON WILL DO THE SAME
THING.
AS WE HEARD ACTUALLY OUR LAST
WORK THAT CONTRIBUTED DIRECTLY
TO THE DIRK PAP POLICY AND
CONTRIBUTING TO ALL THE
CONVERSATIONS RIGHT NOW.
SO WITH THAT BEFORE WE CLOSE I
WANT TO THANK EVERYBODY FOR
PARTICIPATING TODAY AND THOSE
WHO HAVE JOINED US ON WEBCAST.
I REALLY WANT TO PROVIDE NOW ONE
FINAL THANK YOU TO EVERYONE.
TO ALL MY COLLEAGUES AND
COLLEAGUE MEMBERS WHO SERVED ON
THE NSABB WITH ME DURING MY
TENURE, I ESPECIALLY WANT TO
THANK THE NIH STAFF AND OSP FOR
ALL THE SUPPORT YOU DID AND IT
WAS SUCH PROFESSIONAL DEDICATED
SERVICE TO THE BOARD.
IT WAS WONDERFUL.
IT REMINDED ME OF MY PREVIOUS
TIME IN GOVERNMENT SERVICE AND
WHY I USED TO LOVE WORKING IN
GOVERNMENT SERVICE.
SOME OF THE GREAT PEOPLE YOU GOT
THE CHANCE TO WORK WITH.
CARI AND KEVIN AND OTHERS AND
DR. TABAK AND DR. JORGENSON,
THANK YOU.
AND THANK THE SUPPORT FROM NIH,
HHS, AND OTHERS FOR ALLOWING ME
TO SERVE ON NSABB AND SERVE AS
CHAIR.
I WANT TO THANK ALL THE OTHER
NSABB MEMBERS WHO SERVED AND
CAME BEFORE ME AND NSABB WAS
ESTABLISHED IN 2005, IS THAT
CORRECT?
I THINK IT WAS 2005 BUT THE NEW
MEMBERS COMING IN ON THE BOARD
WILL QUICKLY LEARN THAT THERE'S
A FOUNDATION OF KNOWLEDGE THAT
WE CONTINUE TO BUILD UPON AND
THE NEW CHARGE WE'RE GOING TO BE
BUILDING UPON THE WORK WE DID
OVER THE LAST FOUR YEARS.
ANYWAY, I WANT TO THANK
EVERYBODY WHO PREVIOUSLY SERVED
ON NSABB TOO.
SO WITH THAT, THE MEETING IS
ADJOURNED.
THANK YOU.